Heart failure. Heart failure
Conditions
Interventions
Intervention 1: Intervention group: Patients eill be given 1 capsule of lactocare synbiotic daily for 10 weeks. Lactocare Synbiotic Capsules are manufactured by Zist Takhmir Company .Lactocare is an o
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age range from 30 to 70 years Patients with systolic heart failure (LVEF <40%) approved by a cardiologist and receiving at least 3 months of standard heart failure treatment , Medications have reached the maximum tolerated dose and their medication dose will remain constant throughout the study. class 1,2 and 3 of NYHA classification Willingness to participate in the study and sign informed written consent Lack of other diseases including chronic and acute liver disorders (hepatitis B, C, etc.), diabetes, thyroid disorders, severe renal dysfunction (300 mmol /l = creatinine ), pulmonary diseases, inflammatory and autoimmune diseases, Cancer, acute infection Not using any nutritional supplements for the past two months. No substance abuse and smoking Not taking Corticosteroids in the past 4 weeks Failure to receive antibiotics in the past 3 months No history of gastrointestinal surgery No anti-inflammatory drugs except low-dose aspirin (one 80 mg daily) No artificial heart valve No history of rheumatic heart disease Not being pregnant and breastfeeding Lack of insulin BMI< 30
Exclusion criteria
Exclusion criteria: Not willing to continue cooperation use of less than 80% of supplements given to the patient during the study period Acceptance rate = The number of capsules given to the patient - the Number of capsules not used / The number of capsules given to the patient other disease such as metabolic diseases,Cancer and inflammatory diseases during the study that Need special treatment or antibiotic use. Changes in the type and dose of drug which is using by the patient .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-probnp. Timepoint: Before and after intervention. Method of measurement: ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure. Timepoint: Before intervention and 10 weeks after the start of intervention. Method of measurement: sphygmomanometer.;High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before intervention and 10 weeks after the start of intervention. Method of measurement: immunoturbidimetric tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Farzad Shidfar
Iran University of Medical Sciences
Outcome results
None listed